FTRE
Bearish signalScored 2026-09-13 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Fortrea Holdings Inc.
- Nom
- Fortrea Holdings Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.2B
- Employés
- 14,000
- PDG
- Anshul Thakral
- Site web
- https://www.fortrea.com
- Marché
- CERTMEDP
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 221 426 titres (~4 107 645,76 $ US)
- Insiders
- Thakral AnshulSANDERS MACHELLE
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,303,836
Avg sell (VWAP, 90d window) $18.52 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-06
- Last synced
-
2026-08-12 09:47:22
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-09 | Morais Mark A. | Sell · S | 3,149 | $16.85 | $53,061 | Form 4 |
| 2026-09-09 | Russell Carrie Elizabeth | Sell · S | 246 | $16.85 | $4,145 | Form 4 |
| 2026-08-19 | Morais Mark A. | Sell · S | 4,892 | $18.19 | $88,985 | Form 4 |
| 2026-08-06 | Thakral Anshul | Sell · S | 55,975 | $18.06 | $1,010,908 | Form 4 |
| 2026-08-05 | Thakral Anshul | Sell · S | 50,417 | $19.28 | $972,040 | Form 4 |
| 2026-08-03 | SANDERS MACHELLE | Sell · S | 9,700 | $18.01 | $174,697 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-06-23 | James French Hill | Sale | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-09-13 Drivers: fundamentals. Moteurs : fondamentaux.
Despite a meaningful earnings catalyst — with FTRE beating Q2 2026 EPS estimates and raising full-year guidance — the underlying financial health is critically impaired, with a liquidity score of 25, negative EBITDA, a…
The first sentence of the analysis written for FTRE on 2026-09-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Pulls against a bullish reading. Current ratio 0.98 · operating margin -1.1%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 15.6% | 19.8% | 20.8% | 25.5% | 19.8% | |
| Ebit Margin | -32.7% | -5.6% | 1.4% | 6.6% | 4.5% | |
| Ebitda Margin | -29.9% | -2.4% | 4.8% | 9.9% | 9.9% | |
| Operating Profit Margin | -1.1% | -6.0% | 1.1% | 6.6% | 3.7% | |
| Pretax Profit Margin | -36.1% | -10.2% | -1.1% | 6.6% | 4.5% | |
| Continuous Operations Profit Margin | -36.2% | -10.1% | -1.1% | 5.1% | 3.2% | |
| Net Profit Margin | -36.2% | -12.2% | -0.9% | 6.6% | 3.2% | |
| Bottom Line Profit Margin | -36.2% | -12.2% | -0.9% | 6.6% | 3.2% | |
| Current Ratio | 0.982 | 0.999 | 1.607 | 1.784 | 1.352 | |
| Quick Ratio | 0.982 | 0.999 | 1.607 | 1.784 | 1.352 | |
| Solvency Ratio | -0.422 | -0.109 | 0.028 | 0.296 | 0.239 | |
| Cash Ratio | 0.191 | 0.125 | 0.140 | 0.160 | 0.114 | |
| Price To Earnings Ratio | -1.596 | -5.082 | -872.500 | 15.166 | 28.829 | |
| Price To Earnings Growth Ratio | -0.008 | -0.001 | 8.563 | 0.168 | -0.226 | |
| Forward Price To Earnings Growth Ratio | -0.008 | -0.001 | 8.563 | 0.168 | -0.226 | |
| Price To Earnings Diluted Ratio | -1.596 | -5.082 | -872.500 | 15.166 | 28.829 | |
| Price To Earnings Diluted Growth Ratio | -0.008 | -0.001 | 8.563 | 0.168 | -0.226 | |
| Price To Book Ratio | 2.792 | 1.225 | 1.808 | 0.846 | 0.868 | |
| Price To Sales Ratio | 0.578 | 0.619 | 1.090 | 0.997 | 0.925 | |
| Price To Free Cash Flow Ratio | 17.817 | 7.034 | 24.193 | 99.958 | 19.740 | |
| Price To Operating Cash Flow Ratio | 13.861 | 6.352 | 18.403 | 34.206 | 16.660 | |
| Debt To Assets Ratio | 0.411 | 0.335 | 0.386 | 0.015 | 0.018 | |
| Debt To Equity Ratio | 1.980 | 0.880 | 0.975 | 0.019 | 0.024 | |
| Debt To Capital Ratio | 0.664 | 0.468 | 0.494 | 0.019 | 0.023 | |
| Long Term Debt To Capital Ratio | 0.650 | 0.435 | 0.477 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 4.819 | 2.627 | 2.528 | 1.283 | 1.340 | |
| Working Capital Turnover Ratio | -313.034 | 11.447 | 5.572 | 6.765 | 0.000 | |
| Operating Cash Flow Ratio | 0.124 | 0.277 | 0.216 | 0.118 | 0.205 | |
| Operating Cash Flow Sales Ratio | 0.042 | 0.097 | 0.059 | 0.029 | 0.056 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.778 | 0.903 | 0.761 | 0.342 | 0.844 | |
| Debt Service Coverage Ratio | -8.491 | -0.306 | 1.418 | 1,198.500 | 1,322.500 | |
| Interest Coverage Ratio | -0.335 | -1.308 | 0.458 | 935.500 | 571.500 | |
| Short Term Operating Cash Flow Coverage Ratio | 23.646 | 3.513 | 6.452 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.102 | 0.219 | 0.101 | 1.304 | 2.199 | |
| Capital Expenditure Coverage Ratio | 4.504 | 10.306 | 4.179 | 1.520 | 6.408 | |
| Dividend Paid And Capex Coverage Ratio | 4.504 | 10.306 | 4.179 | 1.520 | 6.408 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.091 | -42.755 | 33.983 | 9.901 | 9.282 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 15.6% | ▼-4.2% | ▼-4.7% |
| Ebit Margin | -32.7% | ▼-27.1% | ▼-27.6% |
| Ebitda Margin | -29.9% | ▼-27.5% | ▼-28.3% |
| Operating Profit Margin | -1.1% | ▲4.9% | ▼-2.0% |
| Pretax Profit Margin | -36.1% | ▼-25.9% | ▼-28.8% |
| Continuous Operations Profit Margin | -36.2% | ▼-26.1% | ▼-28.4% |
| Net Profit Margin | -36.2% | ▼-24.0% | ▼-28.3% |
| Bottom Line Profit Margin | -36.2% | ▼-24.0% | ▼-28.3% |
| Current Ratio | 0.982 | ▼-0.016 | ▼-0.362 |
| Quick Ratio | 0.982 | ▼-0.016 | ▼-0.362 |
| Solvency Ratio | -0.422 | ▼-0.313 | ▼-0.428 |
| Cash Ratio | 0.191 | ▲0.066 | ▲0.045 |
| Price To Earnings Ratio | -1.596 | ▲3.486 | ▲165.441 |
| Price To Earnings Growth Ratio | -0.008 | ▼-0.008 | ▼-1.707 |
| Forward Price To Earnings Growth Ratio | -0.008 | ▼-0.008 | ▼-1.707 |
| Price To Earnings Diluted Ratio | -1.596 | ▲3.486 | ▲165.441 |
| Price To Earnings Diluted Growth Ratio | -0.008 | ▼-0.008 | ▼-1.707 |
| Price To Book Ratio | 2.792 | ▲1.567 | ▲1.284 |
| Price To Sales Ratio | 0.578 | ▼-0.041 | ▼-0.264 |
| Price To Free Cash Flow Ratio | 17.817 | ▲10.783 | ▼-15.932 |
| Price To Operating Cash Flow Ratio | 13.861 | ▲7.509 | ▼-4.035 |
| Debt To Assets Ratio | 0.411 | ▲0.076 | ▲0.178 |
| Debt To Equity Ratio | 1.980 | ▲1.101 | ▲1.205 |
| Debt To Capital Ratio | 0.664 | ▲0.197 | ▲0.331 |
| Long Term Debt To Capital Ratio | 0.650 | ▲0.215 | ▲0.338 |
| Financial Leverage Ratio | 4.819 | ▲2.192 | ▲2.300 |
| Working Capital Turnover Ratio | -313.034 | ▼-324.482 | ▼-255.185 |
| Operating Cash Flow Ratio | 0.124 | ▼-0.152 | ▼-0.064 |
| Operating Cash Flow Sales Ratio | 0.042 | ▼-0.056 | ▼-0.015 |
| Free Cash Flow Operating Cash Flow Ratio | 0.778 | ▼-0.125 | ▲0.052 |
| Debt Service Coverage Ratio | -8.491 | ▼-8.184 | ▼-511.215 |
| Interest Coverage Ratio | -0.335 | ▲0.973 | ▼-301.498 |
| Short Term Operating Cash Flow Coverage Ratio | 23.646 | ▲20.133 | ▲16.924 |
| Operating Cash Flow Coverage Ratio | 0.102 | ▼-0.118 | ▼-0.683 |
| Capital Expenditure Coverage Ratio | 4.504 | ▼-5.802 | ▼-0.879 |
| Dividend Paid And Capex Coverage Ratio | 4.504 | ▼-5.802 | ▼-0.879 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.091 | ▲39.665 | ▼-4.555 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.57B | $1.67B | $3.10B | $2.83B | $2.83B | |
| Enterprise value | $2.51B | $2.75B | $4.66B | $2.78B | $2.81B | |
| EV / Sales | 0.92x | 1.02x | 1.64x | 0.98x | 0.92x | |
| EV / Op. cash flow | 22.16x | 10.46x | 27.69x | 33.62x | 16.56x | |
| EV / Free cash flow | 28.48x | 11.59x | 36.40x | 98.24x | 19.62x | |
| EV / EBITDA | -3.09x | -42.76x | 33.98x | 9.90x | 9.28x | |
| Net debt / EBITDA | -1.16x | -16.80x | 11.39x | -0.17x | -0.06x | |
| Current ratio | 0.98x | 1.00x | 1.61x | 1.78x | 1.35x | |
| Income quality | -0.12x | -0.97x | -6.68x | 0.44x | 1.73x | |
| Graham number | — | — | — | $42 | $30 | |
| Graham net-net | -$17 | -$18 | -$20 | -$1 | -$3 | |
| Tax burden | 100.3% | 119.5% | 82.6% | 99.6% | 71.8% | |
| Interest burden | 110.3% | 181.9% | -77.8% | 99.9% | 99.9% | |
| Working capital | -$16.1M | -$1.3M | $472.4M | $547.9M | $290.8M | |
| Invested capital | $1.72B | $2.52B | $3.11B | $3.53B | $3.47B | |
| Return on assets | -36.3% | -9.2% | -0.6% | 4.3% | 2.2% | |
| Operating ROA | -1.0% | -4.1% | 0.7% | 4.3% | 0.0% | |
| Return on tangible assets | -87.0% | -27.1% | -1.4% | 12.7% | 7.2% | |
| Return on equity | -175.0% | -24.1% | -1.5% | 5.6% | 3.0% | |
| Return on invested capital | -1.7% | -5.9% | 0.9% | 4.0% | 2.3% | |
| Return on capital employed | -1.7% | -6.2% | 0.9% | 5.2% | 3.2% | |
| Earnings yield | -62.7% | -19.7% | -0.8% | 6.6% | 3.5% | |
| Free cash flow yield | 5.6% | 14.2% | 4.1% | 1.0% | 5.1% | |
| Capex / Op. cash flow | 22.2% | 9.7% | 23.9% | 65.8% | 15.6% | |
| Capex / Depreciation | 32.3% | 26.0% | 41.1% | 58.1% | 15.9% | |
| Capex / Sales | 0.9% | 0.9% | 1.4% | 1.9% | 0.9% | |
| SG&A / Sales | 16.8% | 20.8% | 15.8% | 14.7% | 9.9% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 2.7% | 2.2% | 1.5% | 0.9% | 0.9% | |
| Intangibles / Total assets | 58.3% | 66.1% | 57.0% | 65.8% | 69.0% | |
| Days sales outstanding | 83d | 94d | 130d | 135d | 113d | |
| Days payables outstanding | 5d | 23d | 22d | 14d | 9d | |
| Operating cycle | 83d | 94d | 130d | 135d | 113d | |
| Cash conversion cycle | 78d | 71d | 108d | 121d | 104d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-07-31 Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here''s What You Should Know Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 2026-07-31 FTRE vs. ARGX: Which Stock Is the Better Value Option? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
- 2026-07-31 Best Momentum Stock to Buy for July 31st FTRE, ASML and KLAC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026.
- 2026-07-31 Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum Fortrea Holdings Inc. (FTRE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our ''Fast-Paced Momentum at a Bargain'' screen.
- 2026-07-29 Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcript Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcript
- 2026-07-29 Fortrea Q2 Earnings Call Highlights Fortrea NASDAQ: FTRE reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving commercial activity, particularly among biotechnology clients.
- 2026-07-29 Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.19 per share a year ago.
- 2026-07-29 Fortrea Reports Second Quarter 2026 Results Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance
- 2026-07-23 Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company''s long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company''s stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor.
- 2026-07-13 Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026.